Imperial College London


Faculty of MedicineInstitute of Clinical Sciences

Professor of Biochemistry



+44 (0)20 3313 4313david.carling




3rd Fl CRBHammersmith HospitalHammersmith Campus






BibTex format

author = {Steinberg, GR and Carling, D},
doi = {10.1038/s41573-019-0019-2},
journal = {Nature Reviews Drug Discovery},
pages = {527--551},
title = {AMP-activated protein kinase: the current landscape for drug development},
url = {},
volume = {18},
year = {2019}

RIS format (EndNote, RefMan)

AB - Since the discovery of AMP-activated protein kinase (AMPK) as a central regulator of energy homeostasis, many exciting insights into its structure, regulation and physiological roles have been revealed. While exercise, caloric restriction, metformin and many natural products increase AMPK activity and exert a multitude of health benefits, developing direct activators of AMPK to elicit beneficial effects has been challenging. However, in recent years, direct AMPK activators have been identified and tested in preclinical models, and a small number have entered clinical trials. Despite these advances, which disease(s) represent the best indications for therapeutic AMPK activation and the long-term safety of such approaches remain to be established.
AU - Steinberg,GR
AU - Carling,D
DO - 10.1038/s41573-019-0019-2
EP - 551
PY - 2019///
SN - 1474-1776
SP - 527
TI - AMP-activated protein kinase: the current landscape for drug development
T2 - Nature Reviews Drug Discovery
UR -
UR -
UR -
VL - 18
ER -